Compare DexCom, Inc. (DXCM) vs Oklo Inc (OKLO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Oklo Inc — how do they compare? DexCom, Inc. trades at $83.97 (market cap $31.86B), while Oklo Inc trades at $34.19 (market cap $6.43B). The key difference: DexCom, Inc. is far larger — about 5× Oklo Inc's market cap, and DexCom, Inc. is trading nearer its 52-week high, Oklo Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Oklo Inc for 31 Days on average.
| DXCM | OKLO | |
|---|---|---|
Market Cap | $31.86B | $6.43B |
Volume | 3,607,070 | 16,238,368 |
Sector | Health | Utilities |
52-Week High | $92.34 | $174.14 |
52-Week Low | $54.84 | $34.57 |
Typical Hold Time | 62 Days | 31 Days |
Enterprise Value | $31.32B | $3.97B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $84.3, up 1.09% today, with a bearish technical signal despite strong fundamentals. The company reported Q2 2026 EPS of $0.70, beating estimates, continuing a trend of earnings outperformance. Revenue growth is robust, with 2025 revenue reaching $4.66 billion and net income margin improving to 20.12%. Analyst consensus is strongly bullish with an 80.77% buy rating and a $95.07 price target, suggesting significant upside from current levels.
The outlook for DXCM is positive driven by expansion in continuous glucose monitoring for Type 2 diabetes, as highlighted in recent company reports. Key risks include competitive pressures and reimbursement challenges. With solid cash flow generation and institutional support, the stock presents a growth opportunity, though investors should monitor execution against high expectations.
OKLO trades at $34.29, down 6.88% on the day, with bearish technical signals and negative earnings momentum. The company shows no revenue in 2025 and substantial losses, though it maintains strong analyst support with a $78.63 consensus price target. Recent news highlights nuclear energy sector volatility and OKLO's $1 billion stock sale activity.
OKLO represents a high-risk, high-reward opportunity in the emerging nuclear sector. While analyst consensus remains strongly bullish, the company faces significant execution risks, negative profitability, and dilution concerns from recent financing activities. The stock's potential hinges on successful project commercialization in the growing nuclear energy market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Oklo Inc
Oklo Inc. is a company focused on developing and commercializing advanced fission power plants. The company specializes in micro-reactor technology, specifically the Aurora design, which uses advanced fuel to produce reliable, clean, and cost-competitive power. Oklo aims to provide scalable, on-site power solutions to various customers, including remote communities, industrial facilities, and government entities, positioning itself as an innovator in the next generation of nuclear energy.
Read more on OKLO →
